Čeština 
Slovenčina 
Română 
Deutsch SIPACTIMET
Treatment of adult patients with diabetes mellitus II. type.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Sipactimet 50 mg/850 mg film-coated tablets
Each tablet contains sitagliptin hydrochloride monohydrate equivalent to 50 mg of sitagliptin and 850 mg of metformin hydrochloride.
Sipactimet 50 mg/1 000 mg film-coated tablets
Each tablet contains sitagliptin hydrochloride monohydrate equivalent to 50 mg of sitagliptin and 1 000 mg of metformin hydrochloride.
PHARMACEUTICAL FORM
Film-coated tablet.
THERAPEUTIC INDICATION
Sipactimet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
DISPENSING AND REIMBURSEMENT
Medicinal product is subjected to medical prescription. The medicinal product is covered by public health insurance.
Mandatory information
